NCT06704620View on ClinicalTrials.gov

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

430

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Advanced and Metastatic NSCLC
Interventions
DRUG

Diphenhydramine

Diphenhydramine intramuscular injection 20mg qd d0-2 Q3W

DRUG

Tislelizumab

Tislelizumab intravenous infusion 200mg d1

DRUG

Pemetrexed

Pemetrexed intravenous infusion 500mg/m2 d1

DRUG

Albumin paclitaxel

Albumin paclitaxel intravenous infusion 260mg/m2 d1

DRUG

Carboplatin

Carboplatin intravenous infusion AUC5 d1

DRUG

Cisplatin

Cisplatin intravenous infusion 75mg/m2 d1

Trial Locations (1)

Unknown

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER